Updated: March 26, 2026
How to Save Money on Anktiva in 2026: Coupons, Discounts, and Patient Assistance
Author
Peter Daggett

Summarize with AI
- How to Save Money on Anktiva Treatment
- Understanding Anktiva's Cost
- Option 1: ImmunityBio Copay Assistance Program
- Option 2: ImmunityBio Patient Assistance Program
- Option 3: Maximize Your Insurance Coverage
- Option 4: Medicare Coverage
- Option 5: Cancer-Specific Financial Assistance
- Option 6: Clinical Trials
- Tips to Minimize Your Total Treatment Cost
- Don't Let Cost Delay Your Treatment
- Related Articles
Anktiva costs $35,800 per dose. Learn about copay programs, patient assistance, insurance tips, and financial resources to make treatment affordable in 2026.
How to Save Money on Anktiva Treatment
Anktiva (nogapendekin alfa inbakicept-pmln) is a groundbreaking immunotherapy for bladder cancer — but it comes with a groundbreaking price tag. At a wholesale acquisition cost (WAC) of $35,800 per dose, a full course of treatment can cost between $750,000 and over $1 million.
If that number takes your breath away, you're not alone. But here's the important news: most patients do not pay anywhere near that amount. Between insurance coverage, copay assistance programs, and patient assistance resources, there are real ways to make Anktiva treatment affordable.
In this guide, we'll walk through every financial resource available to help you pay for Anktiva in 2026.
Understanding Anktiva's Cost
First, let's break down why Anktiva costs what it does:
- It's a biologic medication. Unlike simple chemical drugs, biologics are manufactured using living cells. This process is complex, expensive, and requires specialized facilities.
- It's first-in-class. Anktiva is the only IL-15 superagonist on the market. There are no generic or biosimilar alternatives.
- Treatment is long-term. The full Anktiva protocol includes an induction phase (6 weekly doses) followed by maintenance (3-dose cycles at multiple intervals) for up to 37 months.
- It's a specialty drug. Administered in clinical settings through intravesical instillation, not a pharmacy pickup.
The $35,800 WAC is the list price per dose. Your actual out-of-pocket cost depends on your insurance coverage and what financial assistance programs you qualify for.
Option 1: ImmunityBio Copay Assistance Program
This is the most important financial resource for commercially insured patients.
Program details:
- Eligible commercially insured patients may pay as little as $100 per dose
- Maximum benefit of $25,000 per year
- Covers the difference between your insurance copay/coinsurance and the $100 patient responsibility
Who qualifies:
- Patients with commercial (private) health insurance
- Must have a valid Anktiva prescription for an FDA-approved use
Who does NOT qualify:
- Medicare beneficiaries
- Medicaid beneficiaries
- Patients covered by other federal or state healthcare programs (TRICARE, VA, etc.)
How to enroll: Contact the ImmunityBio CARE program at 1-877-ANKTIVA (1-877-265-8482) or ask your treatment center to enroll you. Your provider's office typically handles the enrollment process.
Option 2: ImmunityBio Patient Assistance Program
If you don't have insurance or your insurance doesn't cover Anktiva, the patient assistance program (PAP) may help.
Program details:
- Provides Anktiva at no cost or reduced cost for qualifying patients
- Designed for uninsured or underinsured patients who meet financial eligibility criteria
How to apply: Contact the ImmunityBio CARE program at 1-877-ANKTIVA or 833-422-2731 (Monday–Friday, 8:00 AM–8:00 PM ET). A case manager will walk you through the application process and determine eligibility.
Option 3: Maximize Your Insurance Coverage
If you have insurance, taking these steps can reduce your costs:
Verify Coverage Before Treatment
- Call your insurance company and ask about coverage for Anktiva (J-code J9028)
- Ask specifically about your copay, coinsurance, and out-of-pocket maximum
- Request a benefits summary in writing
Get Prior Authorization Approved
Prior authorization is required by nearly all insurers. Your doctor's office handles this, but you can help by:
- Providing your insurance information promptly
- Making sure your medical records are complete and up to date
- Following up with your insurance company if approval takes more than 1-2 weeks
Understand Your Out-of-Pocket Maximum
Most insurance plans have an annual out-of-pocket maximum — once you hit this amount, your insurance covers 100% of remaining costs for the year. Given Anktiva's high cost, many patients reach their out-of-pocket maximum quickly.
For example, if your out-of-pocket maximum is $8,000 and your coinsurance is 20%, you'd owe $7,160 for your first dose (20% of $35,800) and then significantly less for subsequent doses until you hit the maximum.
Appeal Denials
If your insurance denies coverage:
- Don't give up — many initial denials are overturned on appeal
- Contact the ImmunityBio CARE program for payer-specific appeal assistance
- Ask your doctor to submit a letter of medical necessity
- Request a peer-to-peer review (your doctor speaks directly with the insurance company's medical director)
Option 4: Medicare Coverage
If you're on Medicare, Anktiva is covered under Medicare Part B as a physician-administered drug. Key points:
- Medicare typically covers 80% after the annual Part B deductible
- You're responsible for the 20% coinsurance (about $7,160 per dose at WAC)
- A Medigap (Medicare Supplement) plan can cover most or all of that 20%
- The ImmunityBio copay program is NOT available for Medicare patients
- However, the patient assistance program may help Medicare patients with demonstrated financial need
If you're on Medicare and struggling with costs, also contact your state's State Health Insurance Assistance Program (SHIP) for free counseling on your options.
Option 5: Cancer-Specific Financial Assistance
Several organizations provide financial assistance to cancer patients that may help offset Anktiva treatment costs:
- CancerCare: Provides financial assistance grants for cancer-related expenses (cancercare.org)
- Patient Advocate Foundation: Helps with insurance issues, copay relief, and financial crisis support (patientadvocate.org)
- Bladder Cancer Advocacy Network (BCAN): Provides resources and support specific to bladder cancer patients (bcan.org)
- The Assistance Fund: Offers copay assistance for specific disease categories (theassistancefund.org)
- NeedyMeds: Database of patient assistance programs (needymeds.org)
Option 6: Clinical Trials
If you're eligible for a clinical trial involving Anktiva, the study medication is typically provided at no cost to participants. ImmunityBio is running several active trials:
- Expanded indications for papillary-only NMIBC
- Recombinant BCG studies (which would also provide BCG access)
- Non-small cell lung cancer combination studies
Search ClinicalTrials.gov for "Anktiva" or "N-803" or ask your oncologist about trial eligibility.
Tips to Minimize Your Total Treatment Cost
- Time your treatment strategically. If possible, start your induction course early in the plan year so subsequent maintenance doses fall within the same benefit period after you've met your out-of-pocket maximum.
- Stack financial assistance. Use the copay program AND cancer foundation grants together if eligible.
- Keep meticulous records. Track every payment, explanation of benefits (EOB), and correspondence with your insurer.
- Ask about payment plans. Some treatment centers offer interest-free payment plans for patient responsibility amounts.
- Review your insurance plan annually. If you're starting Anktiva treatment, consider whether a different plan at open enrollment might offer better coverage for specialty medications.
Don't Let Cost Delay Your Treatment
BCG-unresponsive bladder cancer is a serious condition, and delays in treatment can lead to disease progression. If cost is a barrier, reach out for help immediately:
- ImmunityBio CARE: 1-877-ANKTIVA (1-877-265-8482)
- MedFinder: medfinder.com — find Anktiva in stock near you
- Your treatment center's financial counselor — they deal with high-cost cancer drugs regularly and know the system
Related Articles
Frequently Asked Questions
The wholesale acquisition cost (WAC) for Anktiva is $35,800 per dose. A full treatment course (induction plus maintenance over up to 37 months) can cost $750,000 to over $1 million. However, the ImmunityBio patient assistance program may provide the medication at no cost for qualifying uninsured patients.
No. The ImmunityBio copay assistance program is only available to commercially insured patients. Medicare, Medicaid, and other government program beneficiaries are not eligible. However, Medicare patients may qualify for the patient assistance program based on financial need, and Medigap plans can help cover the 20% Part B coinsurance.
No. Anktiva is a first-in-class biologic medication with no generic or biosimilar alternatives available. Because biologics are complex molecules made from living cells, biosimilar development takes longer than for traditional generic drugs. There is no biosimilar expected in the near term.
If cost remains a barrier even after exploring all assistance programs, talk to your doctor about alternative treatments like Pembrolizumab (which has its own financial assistance programs) or Gemcitabine/Docetaxel (which are relatively affordable generic drugs). Clinical trials may also provide Anktiva at no cost. Never delay cancer treatment due to cost — ask for help.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsRelated articles
32,253 have already found their meds with Medfinder.
Start your search today.

![Who Has Vyvanse in Stock Near You? Find It Today [2026]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2F1079f61f167dcbc2ed5f1da17a0dcb0b7166357e-1024x1024.png%3Frect%3D0%2C256%2C1024%2C512%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)



